DE-71 is a commercial mixture of mostly tetra- and penta-brominated diphenyl ethers (PBDEs), which has been used extensively as a flame retardant ([@b1-ehp-116-1315]). DE-71 and other similar commercial mixtures (known collectively as pentaBDE) were used almost exclusively as flame retardants in flexible polyurethane foam, a major component of bed mattresses and upholstered products. Production of DE-71 ceased in 2004 ([@b58-ehp-116-1315]), the same year that use of pentaBDE and other PBDE commercial mixtures was banned by the [@b18-ehp-116-1315].

PBDEs are very stable compounds, and they are not chemically bonded to the material they are intended to protect from burning. As a result, they are widely found in environmental media ([@b26-ehp-116-1315]; [@b33-ehp-116-1315]) and can be found in human blood and milk ([@b20-ehp-116-1315]; [@b23-ehp-116-1315]; [@b37-ehp-116-1315]; [@b40-ehp-116-1315]; [@b45-ehp-116-1315]; [@b55-ehp-116-1315]). Some of the PBDE congeners most commonly found in human samples are BDE-47, BDE-99, and BDE-153 ([@b26-ehp-116-1315]; [@b23-ehp-116-1315]; [@b40-ehp-116-1315]; [@b45-ehp-116-1315]). Two of these same congeners, the tetrabrominated BDE-47 and the pentabrominated BDE-99, are the main components of DE-71 (36% and 44% by weight, respectively); the hexabrominated BDE-153 is a minor component of DE-71 (4% by weight) ([@b53-ehp-116-1315]).

The prevalence of PBDEs in human tissue is of concern because these compounds are known to alter behavior, thyroid-hormone signaling, and sexual development in animals. Eriksson and colleagues found permanent aberrations in spontaneous behavior in rodents after developmental exposure to BDE-47 ([@b17-ehp-116-1315]), BDE-99 ([@b16-ehp-116-1315]; [@b64-ehp-116-1315]), or BDE-153 ([@b63-ehp-116-1315]). Serum thyroxine (T~4~) was significantly decreased in several different experimental models and by different pentaBDE mixtures: in rats exposed to DE-71 either prenatally or postnatally ([@b15-ehp-116-1315]; [@b56-ehp-116-1315]; [@b67-ehp-116-1315]); in American kestrels (*Falco sparverius*) exposed *in ovo* to a mixture of BDE-47, BDE-99, BDE-100 and BDE-153 ([@b19-ehp-116-1315]); and in adult female rats exposed to the commercial pentaBDE mixture Bromkal 70--5 DE ([@b13-ehp-116-1315]). The effect of PBDEs on T~4~ levels may require metabolic activation because hydroxylated PBDEs, but not the non-hydroxylated congeners, are able to bind human transthyretin *in vitro* ([@b47-ehp-116-1315]). Other effects of pentaBDE mixtures or their congeners in experimental animals suggest estrogenic or antiandrogenic activity. In rats, developmental exposure to BDE-99 affected the regulation of estrogen target genes ([@b10-ehp-116-1315]), impaired spermatogenesis ([@b32-ehp-116-1315]), and decreased circulating sex steroids and reduced anogenital distance in males ([@b36-ehp-116-1315]). Male rats exposed to DE-71 on postnatal days 23--53 had reduced seminal vesicle and ventral prostate weights and delayed puberty ([@b56-ehp-116-1315]).

PBDEs are suspected to behave as estrogens because of the similarity of their chemical structures and properties to other xeno-estrogens, mainly the polychlorinated biphenyls (PCBs) ([@b27-ehp-116-1315]; [@b46-ehp-116-1315]; [@b51-ehp-116-1315]). We have shown that DE-71 has weak estrogenic activity *in vivo* and *in vitro* ([@b48-ehp-116-1315]). Because hydroxylated metabolites of a structurally similar class of halogenated aromatic pollutants, the PCBs, exert estrogenic effects ([@b9-ehp-116-1315]; [@b59-ehp-116-1315]), it may be reasonable to expect that hydroxylated forms of PBDEs would also be estrogenic. Others have shown that some PBDE congeners and certain synthetically hydroxylated congeners could exert estrogenic effects in cultured cells ([@b24-ehp-116-1315]; [@b46-ehp-116-1315]). In a recent *in vivo* study, BDE-47 had uterotrophic effects in immature rats ([@b12-ehp-116-1315]), suggesting *in vivo* activation of this otherwise nonestrogenic PBDE ([@b46-ehp-116-1315]).

We previously reported that DE-71 is metabolized in the mouse to produce hydroxylated metabolites ([@b53-ehp-116-1315]) and that it had mild estrogenic activity in the same animals ([@b48-ehp-116-1315]). In the present study, our goal was to determine if DE-71 or its *in vivo* metabolites could induce estrogenic signaling though ER-α.

Materials and Methods
=====================

Test chemicals
--------------

We purchased dimethyl sulfoxide (DMSO) and estradiol \[1, 3, 5(10)-estra-triene-3, 17β-diol; E~2~\] from Sigma Chemical Co. (St. Louis, MO). The PBDE congener mixture DE-71 was a gift from the Great Lakes Chemical Corporation (West Lafayette, IN); the congener composition was previously described by [@b53-ehp-116-1315]. The individual hydroxylated metabolites of PBDE \[4-OH-2, 2′, 4-tribromodiphenyl (4′-OH-BDE-17); 2′-OH - 2, 4, 4′ - tribromodiphenyl (2′-HO-BDE-28); 4-HO-2, 2′,3, 4′-tetra-bromodiphenyl (4-OH-BDE-42); 3-OH-2, 2′, 4, 4′-tetrabromodiphenyl (3-OH-BDE-47); 6-OH-2, 2′,4, 4′-tetra-bromodiphenyl (6-OH-BDE-47); and 4′-OH-2, 2′,4, 5′-tetrabromodiphenyl (4′-OH-BDE-49)\] were synthesized as described by [@b43-ehp-116-1315] and were gifts from G. Marsh (Stockholm University, Stockholm, Sweden). We purchased the brominated phenols 2, 4-dibromophenol (2, 4-DBP) and 2, 4, 5-tribromophenol (2, 4, 5-TBP) from Cambridge Isotope Laboratories (Cambridge, MA). DMSO was used as primary solvent for all chemicals, and the DMSO solutions were further diluted in cell culture media for treatments.

Cells and culture conditions
----------------------------

MDA-MB-231 breast cancer cells ([@b8-ehp-116-1315]) obtained from ATCC (American Type Culture Collection; Manassas, VA) and BG1Luc4E2 ovarian cancer cells, a gift from M. Denison (University of California, Davis, CA), were used in estrogen bioassays. BG1LucE2 cells are BG-1 ovarian cancer cells ([@b21-ehp-116-1315]) stably transfected with an estrogen-responsive plasmid ([@b54-ehp-116-1315]). Most cell culture media and supplements were purchased from Gibco/Invitrogen (Carlsbad, CA), except bovine growth serum (BGS; Hyclone, Logan, UT) and geneticin (G418; Sigma). Most charcoal-stripping reagents and endotoxin-free water were purchased from Sigma-Aldrich (St. Louis, MO) except Dulbecco's phosphate-buffered saline (DPBS; Mediatech Inc., Herndon, VA). MDA-MB-231 cells were maintained in growth medium (GM): minimum essential media (MEM) supplemented with [l]{.smallcaps}-glutamine (2 mM), nonessential amino acids (0.1 mM), HEPES buffer (10 mM), 0.4 pg/mL insulin, and 5% vol/vol BGS\]. BG1Luc4E2 cells were maintained in BG1-GM: alpha-MEM supplemented with HEPES buffer (10 mM), geneticin (0.4 g/L) and 10% vol/vol BGS. Basal medium (BM) for MDA-MB-231 cells consisted of a formulation similar to GM, except that phenol red--free MEM and 3% charcoal-stripped BGS were used. BM for BG1Luc4E2 cells (BG1-BM) consisted of phenol red--free Dulbecco's modified Eagle media: Nutrient Mixture F12 (DMEM:F12; Gibco/Invitrogen) supplemented with HEPES buffer (10 mM) and 10% vol/vol charcoal-stripped BGS. BGS was stripped of estrogenic activity by methods described previously ([@b4-ehp-116-1315]; [@b38-ehp-116-1315]).

Estrogen response element-luciferase (ERE-luc) assays
-----------------------------------------------------

We used two ERE-luciferase reporter gene systems: one transiently transfected and the other an established stably transfected cell line. For the transient system, ER-negative MDA-MB-231 breast cancer cells were plated in BM. Two days later cells were transfected using Tfx-20 (Promega, Madison, WI) with expression vectors for ER-α(HEG0; from P. Chambon, Université Louis Pasteur, Illkrich, France), the estrogen-responsive firefly luciferase reporter construct ERE2-pS2-luc ([@b39-ehp-116-1315]), and the control *Renilla* luciferase reporter construct pRL-TK (Promega). Cells were treated with test chemicals 1 hr after transfection, and assayed for luciferase activity after 18 hr. Results are expressed as the ratio of firefly luciferase to *Renilla* luciferase. For the stable reporter system, ER-positive BG1Luc4E2 ovarian cancer cells ([@b54-ehp-116-1315]) were incubated in BG1-BM for 5 days before treatment; cells were then assayed for luciferase activity 18 hr after addition of the test compound.

In vitro generation of microsomal metabolites
---------------------------------------------

We incubated DE-71 or E~2~ with liver microsomes to obtain microsomal metabolites, following a procedure adapted from [@b7-ehp-116-1315]. Glcose-6-phosphate, glucose-6-phosphate dehydrogenase (G6PD) and β-nicotinamide adenine dinucleotide phosphate (oxidized form, NADP~+~) were purchased from Sigma-Aldrich. DE-71 (1 mM) or E~2~ (1 μM) were incubated for 24 hr with female rat liver microsomes (BD Biosciences Gentest, Woburn, MA) in a buffer that included an NADPH-generating system (50 mm Tris buffer, pH 7.5, 5 mM MgCl~2~, 12 mM glucose-6-phosphate, 0.4 mM NADP^+^, 2 units G6PD) in loose-capped tubes at 37°C with shaking. The incubation mixture was then centrifuged at 105,000 relative centrifugal force (RCF) at 4°C for 1 hr to remove microsomes. The hydroxylated organic fraction was extracted from the supernatant by solid-state extraction with ethanol elution using Sep-Pak Plus C18 cartridges (Waters Corp.; Milford, MA), then evaporated to dryness *in vacuo* and reconstituted in a volume of DMSO that would yield 10 mM PBDE or 10 μM estradiol, assuming 100% recovery. This extraction procedure was adapted from [@b66-ehp-116-1315].

Recombinant ER-α binding assay
------------------------------

Vehicle or test chemicals were incubated with 1 nM tritiated E~2~ (^3^H-E~2~; Amersham Biosciences, Buckinghamshire, UK) and 0.6 nM recombinant ER-α(Panvera/Invitrogen, Madison, WI) in TE buffer (10 mM Tris, 1 mM EDTA, pH 7.5) at 4°C overnight. Hydroxylapatite (60% in TE buffer) was added, mixed well, and incubated for 15 min at room temperature. The resulting slurry was washed three times by centrifugation at 3,000 RCF at 4°C with TE buffer changed. Bound ligand was extracted by incubation of the slurry with absolute ethanol at 30°C for 10 min. Tritium (^3^H) decay (counts per minute) was measured by liquid scintillation in a Beckman LS 5000 TD counter (Beckman-Coulter Inc., Fullerton, CA).

Statistics
----------

All statistics were performed using GraphPad Prism, version 3.0a, for Macintosh (GraphPad Software, San Diego CA). For each analysis, we determined whether groups had unequal variances by Bartlett's test. Group averages with equal variances were compared to each other either by one-way analysis of variance (ANOVA) with Tukey post-test or by unpaired *t*-test as appropriate. Group averages with unequal variances were compared to each other by *t*-test with Welch's correction. Groups treated with DE-71 or E~2~ alone were compared with vehicle controls, and groups cotreated with DE-71 and E~2~ were compared with controls treated with E~2~ alone. All values are expressed as mean ± SD or SE as indicated. We considered groups statistically different if *p* \< 0.05 by ANOVA with Tukey posttest or *t*-test (two-tailed). Dose--response studies were also subjected to regression analysis using a sigmoidal curve fitting model:
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where EC~50~ is the median effective concentration. The modeled curve is shown in figures if *R*^2^ \> 0.8.

Results
=======

In vitro microsomal metabolism increases estrogenic character of DE-71
----------------------------------------------------------------------

To determine whether microsomal metabolism could increase estrogenic activity, we incubated DE-71 with female rat microsomes, with or without a complete NADPH generating system. The incubation product was then tested in ERE-luciferase assays, using either the transient transfection system with MDA-MB-231 cells or the stably transfected ER-α--positive BG1Luc4E2 cells. At 10^−5^ M, DE-71 induced little ERE-luciferase activity when it was incubated in the buffer lacking an NADPH generating capacity (without NADP~+~; negative control), but the product of the complete incubation buffer produced a 4-fold increase in luciferase ([Figure 1](#f1-ehp-116-1315){ref-type="fig"}). Microsomal incubation decreased the activity of E~2~ by 78%, an expected result because hydroxylation decreases the activity of E~2~ ([@b44-ehp-116-1315]). Furthermore, the level of activity of the extract from the E~2~ incubated without NADP~+~ indicates that recovery of compound by the extraction methods used and in three separate microsomal incubation experiments was 66--98%.

Phenolic metabolites found in blood of mice after treatment with DE-71
----------------------------------------------------------------------

In a previous study ([@b53-ehp-116-1315]), we examined blood serum from BALB/c mice that had been treated with DE-71 for 34 days and quantified identifiable phenolic metabolites that included two brominated phenols and six hydroxylated brominated diphenyl ethers ([Table 1](#t1-ehp-116-1315){ref-type="table"}). These findings raise the possibility that the estrogenic effects seen earlier in mice and in culture ([@b48-ehp-116-1315]) were due to the metabolites and not necessarily the original DE-71 congeners.

DE-71 and its phenolic metabolites activate the ERE
---------------------------------------------------

E~2~ induces ERE-luciferase at concentrations above 10^−13^ M in the stably transfected BG1Luc3E2 reporter cell culture system ([Figure 2](#f2-ehp-116-1315){ref-type="fig"}), with an EC~50~ in the picomolar range ([Table 2](#t2-ehp-116-1315){ref-type="table"}). Neat DE-71 and the metabolites found in mice were tested using BG1Luc3E2 cells to determine if they were able to activate ERE-mediated gene transcription ([Figure 2](#f2-ehp-116-1315){ref-type="fig"}), and their potencies and effectiveness were compared to that of E~2~ ([Table 2](#t2-ehp-116-1315){ref-type="table"}). The potencies of each test compound were estimated by determining the compound's own EC~50~ from its own maximal effect, and also by calculating its relative estrogenic potency determined from the concentration required to produce an effect equivalent to E~2~'s EC~50~.

DE-71 was able to significantly induce ERE-luciferase at test concentrations ≥ 5 × 10^−5^ M, reaching the same effectiveness as E~2~ at 10^−4^ M ([Figure 2B](#f2-ehp-116-1315){ref-type="fig"}). The calculated EC~50~ for DE-71 was 3.7 × 10^−5^ M. Because the maximal effect of DE-71 was very close to the maximal effect of E~2~, its EC~50~ (3.7 × 10^−5^ M) and its estrogen equivalency potency (EEP; 3.9 × 10^−5^ M) were similar. One metabolite, 4′-OH-BDE-17 was clearly more potent than DE-71, with an EC~50~ in the micromolar range ([Table 2](#t2-ehp-116-1315){ref-type="table"}). 4′-OH-BDE-17 had a relative estrogenic potency approximately 10-fold that of DE-71, and it was more effective than DE-71 or E~2~, reaching an estimated maximal effect 30% higher than E~2~ ([Figure 2C](#f2-ehp-116-1315){ref-type="fig"}; [Table 2](#t2-ehp-116-1315){ref-type="table"}). 4′-OH-BDE-49 had an EC~50~ similar to that of DE-71 but a much lower efficacy; its maximal effect did not even reach the EC~50~ for E~2~ ([Figure 2E](#f2-ehp-116-1315){ref-type="fig"}; [Table 2](#t2-ehp-116-1315){ref-type="table"}). Another *para*-hydroxylated metabolite, 4-HO-BDE-42, appears to have been more potent than DE-71, but because of limited availability of this compound, the analysis was not carried out with a sufficient span of concentrations to allow an accurate estimate of the EC~50~ ([Figure 2D](#f2-ehp-116-1315){ref-type="fig"}).

DE-71 phenolic metabolites displace ^3^H-E~2~ from ER-α
-------------------------------------------------------

We assessed the ability of the metabolites found in mouse blood to displace ^3^H-E~2~ from recombinant ER-α, and results are summarized in [Figure 3](#f3-ehp-116-1315){ref-type="fig"} and [Table 3](#t3-ehp-116-1315){ref-type="table"}. Neither the DE-71 mixture nor the bromophenol metabolites 2, 4-DBP and 2, 4, 5-TBP were able to displace ^3^H-E~2~ from ER-α ([Figure 3B, I, J](#f3-ehp-116-1315){ref-type="fig"}). All of the hydroxylated BDEs displaced ^3^H-E~2~ from ER-α, but their relative binding affinities were very low ([Table 3](#t3-ehp-116-1315){ref-type="table"}). Of the OH-BDEs tested, the *para*-hydroxylated congeners (at either the 4 or 4′ position) had a higher affinity for the estrogen receptor than 2-, 3-, or 6-OH-BDEs. 4′-OH-BDE-17 and 4′-OH-BDE-49 were the most potent, with mean inhibitory concentrations (IC~50~) in the micromolar range ([Figure 3C, D, E](#f3-ehp-116-1315){ref-type="fig"}; [Table 3](#t3-ehp-116-1315){ref-type="table"}). 6-OH-BDE-47, 3-OH-BDE-47, and 2′-OH-BDE-28 had IC~50~ values one order of magnitude higher than the *para*-OH-BDEs ([Figure 3F, G, H](#f3-ehp-116-1315){ref-type="fig"}; [Table 3](#t3-ehp-116-1315){ref-type="table"}). In general, the potency of each OH BDE displacing ^3^H E~2~ from ER-α correlates with their ability to activate ERE-luciferase, and the congeners with the highest IC~50~ values induce very little (3 OH-BDE 47) or no significant ERE-luciferase activity (2′-OH-BDE-28 and 6-OH-BDE-47).

DE-71 phenolic metabolites modify ERE activation by E~2~
--------------------------------------------------------

Because DE-71 and several of its hydroxylated metabolites were able to either activate and/or displace ^3^H-E~2~ from ER-α, We cotreated BG1Luc3E2 cells with 10^−11^ M E~2~ and one of the chemicals of interest to determine if the PBDEs were able to modify E~2~-induced ERE-luciferase activity. The two bromophenol metabolites found in mice, 2, 4-DBP and 2, 4, 5-TBP, were not tested because they had no significant effect in either the ERE-induction or the ^3^H-E~2~ displacement assays. DE-71 induced ERE-luciferase beyond the maximal effect of E~2~ alone ([Figure 4B](#f4-ehp-116-1315){ref-type="fig"}). The same was true for 4′-OH-BDE-17 and 4′-OH-BDE-49 ([Figure 4C, E](#f4-ehp-116-1315){ref-type="fig"}). Another PBDE tested, 4-OH-BDE-42, appeared to induce ERE-luciferase above the E~2~ maximum, but the effect was not statistically significant ([Figure 4D](#f4-ehp-116-1315){ref-type="fig"}). The only *meta-*OH-PBDE tested, 3-OH-BDE-47, was not estrogenic by itself but was able to potentiate the ERE-luciferase induction of E~2~ ([Figures 2G](#f2-ehp-116-1315){ref-type="fig"} and [4G](#f4-ehp-116-1315){ref-type="fig"}). The two *ortho*-hydroxylated BDE metabolites exhibited a biphasic dose--response curve in the E~2~ cotreatment assay. At high concentrations, 2′-OH-BDE-28 and 6-OH-BDE-47 were able to antagonize the effect of E~2~. 6-OH-BDE-47 was the more potent antagonist, showing an effect at 5 × 10^−6^M, whereas antagonism by 2′-OH-BDE-28 was observed only at 5 × 10^−5^ M ([Figure 4F, H](#f4-ehp-116-1315){ref-type="fig"}). Both of these metabolites also seem to potentiate the effect of 10^−11^ M E~2~ at lower concentrations in a manner similar to other PBDEs tested, although this effect was statistically significant only for 2′-OH-BDE-28. However, because only DE-71 and 2′-OH-BDE-28 were tested at a concentration of ≥5 × 10^−5^ M, it is possible that other hydroxylated PBDEs have the same biphasic behavior in the ERE-luciferase assay. The protein content of the culture wells at the time of harvest (not shown) indicated that there was no toxicity produced by 6-OH-BDE-47 or 2′-OH-BDE-28 at these concentrations (5--50 μM) when tested alone or in combination with E~2~. Interestingly, both OH-BDEs found to be estrogen antagonists were able to displace ^3^H-E~2~ from ER-α ([Figure 3F, H](#f3-ehp-116-1315){ref-type="fig"}), but when administered alone they did not induce significant ERE-luciferase ([Figure 2F, H](#f2-ehp-116-1315){ref-type="fig"}).

Discussion
==========

PBDEs are suspected to behave as estrogens because of the similarity of their chemical structure to other xenobiotics, mainly the PCBs ([@b11-ehp-116-1315]; [@b57-ehp-116-1315]; [@b65-ehp-116-1315]). Furthermore, hydroxylated metabolites of PCBs have been shown to exert estrogenic effects ([@b5-ehp-116-1315]; [@b30-ehp-116-1315]). Therefore, it may be reasonable to expect that hydroxylated forms of PBDEs are also estrogenic. Our previous findings indicate that the PBDE mixture DE-71 is estrogenic *in vitro* and *in vivo*, although much less potent than E~2~ ([@b48-ehp-116-1315]). Here, we show estrogenic and antiestrogenic effects of the phenolic metabolites of DE-71 by an interaction with ER-α.

[@b46-ehp-116-1315] tested 17 PBDE congeners for estrogenic activity in an ERE-luciferase assay (ER-CALUX; [@b34-ehp-116-1315]). Two of the congeners in DE-71, BDE-28 and BDE-100, were mildly estrogenic; BDE-100 was the most potent of the PBDEs although not the most effective. Using the same ER-CALUX bioassay, [@b24-ehp-116-1315] showed weak estrogenic activity for the DE-71 congeners BDE-28, BDE-47, and BDE-100, but not for the pentaBDE mixture Bromkal 70-5DE. Results from [@b46-ehp-116-1315] and [@b24-ehp-116-1315] agree in the relative potency of these chemicals, and both groups agree that the EC~50~ for BDE-100 is in the micromolar range. In the present study we showed that DE-71 increased expression of ERE-luciferase reporter gene in BG1Luc3E2 cells, with potency similar to that of BDE-28 and BDE-100 in the ER-CALUX assay ([@b24-ehp-116-1315]; [@b46-ehp-116-1315]). The difference between our ERE-luciferase results and those of [@b24-ehp-116-1315] can be accounted for by the fact that we tested higher concentrations. It may also be that the BG-1 cells we used and the T47D cells of the ER-CALUX assay differ in their ability to metabolically activate the various PBDE congeners.

In the present study, we observed metabolic activation of DE-71 to an estrogenic product *in vitro*, and previous experiments demonstrated that DE-71 congeners are hydroxylated in the mouse (Qui et al. 2007), a chemical modification that could increase their estrogenic activity. In the *in vitro* experiments, DE-71 was preincubated with rat liver microsomes, imitating the classical experiments by which Kupfer and Bulger demonstrated the metabolic activation of the proestrogen methoxychlor ([@b7-ehp-116-1315]; [@b31-ehp-116-1315]). Preincubation of DE-71 with microsomes under enzyme-activating conditions increased its estrogenic activity. Mammalian liver microsomes are rich in cytochrome P450 (CYP450), a group of isoenzymes responsible for metabolism of many endogenous and exogenous chemicals including estrogens (reviewed by [@b3-ehp-116-1315]). The biological activities of environmental chemicals have been found to be either increased or decreased by specific CYP450s ([@b22-ehp-116-1315]), and some of these chemicals are known to be converted into estrogens by CYP450 metabolism ([@b7-ehp-116-1315]; [@b29-ehp-116-1315]; [@b31-ehp-116-1315]; [@b49-ehp-116-1315]). Based on findings by Qui et al. (2007) and others ([@b41-ehp-116-1315]; [@b42-ehp-116-1315]), the DE-71 congener BDE-47 seems to be the source of activated OH-PBDEs in laboratory rodents; BDE-47 itself has been found to have little estrogenic activity ([@b24-ehp-116-1315]; [@b46-ehp-116-1315]). Others have also found OH-PBDEs in wild marine animals that could be BDE-47 metabolites ([@b28-ehp-116-1315]; [@b60-ehp-116-1315]; [@b61-ehp-116-1315]). However, the source of OH-BDEs in the marine environment can be both natural and anthropogenic, because some marine organisms produce natural brominated compounds ([@b62-ehp-116-1315]).

We observed both estrogenic and anti-estrogenic effects in our study. We found that metabolites of DE-71 hydroxylated at the *ortho* position could act as antiestrogens. Although cotreatment with DE-71 produced a larger effect than the maximal response to E~2~ in the present study using a reporter gene assay, in another bioassay, based on MCF-7 cell proliferation, we observed both an agonist effect when DE-71 was administered alone and an antiestrogenic effect when coadministered with E~2~ ([@b48-ehp-116-1315]). Because both MCF-7 cells and ovarian cancer cells express CYP450 enzymes ([@b14-ehp-116-1315]; [@b35-ehp-116-1315]; [@b50-ehp-116-1315]), it may be that the effects in cell proliferation and gene expression were due to metabolites generated in culture. The difference in responses between cell proliferation and reporter gene assays could result from generation of different metabolites in each assay due to differences in treatment duration (10 days vs. 18 hr, respectively) and/or the predominant CYP450 iso-enzyme activities in each kind of tissue (mammary vs. ovarian cancers). In addition, the estrogenic activity seen by other investigators for individual congeners in reporter gene bioassays ([@b24-ehp-116-1315]; [@b46-ehp-116-1315]) could be due to metabolic activation of those compounds. Thus, it is likely that the observed biological activity of DE-71 resulted from the sum of estrogenic and antiestrogenic activities of metabolites produced from individual BDE congeners.

Compounds may act as endocrine disruptors through a number of mechanisms, including indirectly by altering metabolism of endogenous hormones. [@b25-ehp-116-1315] found that BDE-47 and several of the OH-PBDE metabolites that we found to have either estrogenic or antiestrogenic activity in culture also inhibit estrogen sulfotransferases (E2SULT) *in vitro*. Such an effect would translate into an increased activity of administered E~2~ and could explain the ability of 3-OH-BDE-47 to increase ERE-luciferase expression above the level induced by E~2~ alone when BG-1Luc4E2 cells are cotreated with both chemicals, even though 3-OH-BDE-47 does not induce ERE-luciferase by itself. However, the E~2~ dose used in cotreatment with 3-OH-BDE-47 was already high enough to reach the maximal effect in this system; therefore, it is unlikely that making more E~2~ available by inhibiting E2SULT would increase ERE-luciferase signaling. Furthermore, it is not known whether the BG-1Luc4E2 cells express E2SULT, and we observed no significant potentiation of the estrogenic effect by 4-OH-BDE-42, another metabolite that behaves as a potent inhibitor of E2SULT *in vitro*. A weaker E2SULT inhibitor, 6-OH-BDE-47, actually produced an antiestrogenic effect in our system. Thus, it is unlikely that altered E2SULT activity explains the additional estrogenic effect produced by 3-OH-BDE-47.

The levels of DE-71 needed to have estrogenic effects in our studies (micromolar range) are much higher than the highest concentrations found so far in human blood serum (0.1--5 nM; [@b45-ehp-116-1315]). However, there is little current information on the levels of OH-PBDEs in human serum or the role that human enzymes (especially CYP450) may play in the formation of DE-71 metabolites. Rodent tissues do not have the same CYP450 activities as human tissues ([@b6-ehp-116-1315]); therefore, the metabolites we found in mouse serum (Qui et al. 2007) or those found by [@b42-ehp-116-1315] in rat feces may not be representative of metabolites formed in humans. Several of the PBDE metabolites we found in mice (4′-OH-BDE-17, 6-OH-BDE-47, 3-OH-BDE-47, and 4-OH-BDE-42) have been found in human serum samples from children working at a municipal waste disposal site ([@b2-ehp-116-1315]) at much lower concentrations (\< 0.1 nM) than are required to cause estrogenic effects in culture (≥ 1 μM) or associated with slight estrogenic effects in mice (\> 40 nM; [Table 1](#t1-ehp-116-1315){ref-type="table"}) following approximately 1 month of treatment ([@b48-ehp-116-1315]). It is reasonable to expect that PBDE exposure for municipal waste workers is due in part to contact with DE-71 and other pentaBDE mixtures in discarded consumer products. However, [@b2-ehp-116-1315] found an additional PBDE metabolite in humans, 4-OH-BDE-90, that we did not observe in mice, and our own unpublished studies indicate that 5-OH-BDE-47 and 5′-OH-BDE-99 are major metabolites in human blood (Qui et al., in press); the estrogenic activity of these compounds has not been tested.

In summary, the observations that the DE-71 mixture does not displace ^3^H-E~2~ from ER-α---while the hydroxylated metabolites do---suggest that the weak estrogenic effects of DE-71 are due to metabolic activation of individual congeners. However, the behavior of DE-71 and some of its metabolites when coadministered with E~2~ suggest a secondary, undetermined mechanism of action different from classical ER-α activation.
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![ERE-luciferase induction by microsomal metabolites of DE-71. Incubations with an incomplete NADPH generating system (lacking NADP+) were run in parallel and served as the negative control. The incubation products were tested in ERE-luciferase assays. One representative assay is shown; results are presented as mean ± SD (*n* = 4). The results are representative of three similar assays.\
\*\**p* \< 0.01, and ^\#^*p* \< 0.001 compared with vehicle control.\
^\#\#^*p* \< 0.001 compared with the same treatment without the complete NADPH generating system.](ehp-116-1315f1){#f1-ehp-116-1315}

![ERE-luciferase induction by E~2~ (*A*), DE-71 (*B*), and the OH-BDEs 4′-OH-BDE-17 (*C*), 4-OH-BDE-42 (*D*), 4′-OH-BDE-49 (*E*), 2′-OH-BDE-28 (*F*), 3-OH- BDE-47 (*G*), 6-OH-BDE-47 (*H*), 2, 4-DBP (*I*), and 2, 4, 5-TBP (*J*). See "Material and Methods" for details. Each curve for an OH-BDE represents the mean of 3--6 independent dose--response studies, except 6-OH-BDE-47, for which only 2 assays were performed. Curves for DE-71 and E~2~ are the mean of 12 and 8 independent dose--response studies, respectively. Error bars indicate SE. All values are normalized to vehicle control (DMSO = 1). Modeled data for E~2~ (dashed blue line) and DE-71 (dotted line) are shown in all OH-BDE charts for comparison. Modeled data for each OH-BDE are shown as a solid line.](ehp-116-1315f2){#f2-ehp-116-1315}

![Displacement of 1 nM ^3^H-E~2~ from recombinant ER-α *in vitro* by E~2~ (*A*), DE-71 (*B*), and the OH-BDEs 4′-OH-BDE-17 (*C*), 4-OH-BDE-42 (*D*), 4′-OH-BDE-49 (*E*), 2′-OH-BDE-28 (*F*), 3-OH-BDE-47 (*G*), 6-OH-BDE-47 (*H*), 2, 4-DBP (*I*), and 2, 4, 5-TBP (*J*) found in mice (by the ER-α binding assay). Each curve for an OH-BDE represents the mean of 3--4 independent dose--response studies, except for 4-OH-BDE-49, 6-OH-BDE-47, and the bromophenols only 2 assays were performed. Curves for DE-71 and E~2~ are the mean of 6 and 11 independent dose--response studies, respectively. Error bars indicate SE. All values are normalized to vehicle control (DMSO = 1). Modeled data for E~2~ (dashed blue line) and DE-71 (dotted line) are shown in all OH-BDE charts for comparison. Modeled data for each OH-BDE are shown as a solid line.](ehp-116-1315f3){#f3-ehp-116-1315}

![ERE-luciferase induction in BG1Luc4E2 cells after coteatment with E~2~. See "Material and Methods" for details. Squares indicate data for cotreatment with 10^−11^ M E~2~ and the specified chemical; data are normalized to the maximal effect of E~2~ (set at 1.0). Each curve is the mean of 3--5 independent dose--response studies, except for 2-OH-BDE28, 6-OH-BDE47, and 4-OH-BDE49 for which only 2 assays were performed. Error bars indicate SE. Modeled data for E~2~-only dose--response (blue dashed line) are shown in all charts for comparison.\
\**p* \> 0.5; \*\**p* \> 0.01; and ^\#^*p* \> 0.001 compared with the maximal effect of E~2~ alone.](ehp-116-1315f4){#f4-ehp-116-1315}

###### 

Blood serum concentrations \[μM (mean ± SE)\] of phenolic metabolites found in mice after DE-71 treatment.

  Compound                                            Vehicle control   DE-71
  --------------------------------------------------- ----------------- -------------
  2,4-DBP                                             0.01 ± 0.02       0.29 ± 0.09
  2,4, 5-TBP                                          0.001 ± 0.002     0.24 ± 0.09
  4′-OH-BDE-17                                        ND                0.04 ± 0.02
  2′-OH-BDE-28                                        0.0002 ± 0.0005   0.03 ± 0.01
  4-OH-BDE-42                                         0.002 ± 0.01      0.36 ± 0.24
  3-OH-BDE-47                                         ND                0.11 ± 0.05
  6-OH-BDE-47                                         ND                0.04 ± 0.02
  4′-OH-BDE-49                                        0.001 ± 0.002     0.08 ± 0.04
  DE-71[a](#tfn2-ehp-116-1315){ref-type="table-fn"}   \< 0.02           3.9 ± 0.8

ND, not detected. Mice were treated with 50 mg/kg/day DE-71 (per os) for 34 days. Concentrations were determined by gas chromatographic mass spectrometry analysis. Modified from [@b53-ehp-116-1315].

All non-OH congeners.

###### 

Potency and efficacy estimates of DE-71 metabolites in the ERE-luciferase assay.

  Compound       EC~50~[a](#tfn4-ehp-116-1315){ref-type="table-fn"} (M)   EEP (M)[b](#tfn5-ehp-116-1315){ref-type="table-fn"}   Relative estrogen potency[c](#tfn6-ehp-116-1315){ref-type="table-fn"} (ratio)   Fold-induction at EC~50~   Relative effect[d](#tfn7-ehp-116-1315){ref-type="table-fn"} (ratio)
  -------------- -------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------------------
  E~2~           1.2 × 10^−12^                                            ---                                                   1.00                                                                            3.3                        1.00
  DE-71          3.7 × 10^−5^                                             3.9 × 10^−5^                                          3.1 × 10^−8^                                                                    3.4                        1.03
  2, 4-DBP       No effect                                                ---                                                   ---                                                                             ---                        ---
  2, 4, 5-TBP    No effect                                                ---                                                   ---                                                                             ---                        ---
  4′-OH-BDE-17   4.7 × 10^−6^                                             3.5 × 10^−6^                                          3.4 × 10^−7^                                                                    4.3                        1.30
  2′-OH-BDE-28   NA                                                       NR                                                    ---                                                                             ---                        ---
  4-OH-BDE-42    NA                                                       NA                                                    ---                                                                             NA                         NA
  3-OH-BDE-47    NA                                                       NR                                                    ---                                                                             NA                         ---
  6-OH-BDE-47    No effect                                                ---                                                   ---                                                                             ---                        ---
  4′-OH-BDE-49   1.3 × 10^−5^                                             NR                                                    ---                                                                             1.2                        0.36

Abbreviations: NA, not available because effect was insufficient to calculate an EC~50~; NR, E~2~ EC~50~ not reached. All values were estimated from curves derived in [Figure 2](#f2-ehp-116-1315){ref-type="fig"}.

Determined using the chemical's own maximum effect set at 100%.

Concentration inducing the same luciferase activity as the EC~50~ of E~2~.

Ratio of the E~2~ EC~50~ to EEP.

Test chemical-to-E~2~ ratio of luciferase induction at EC~50~.

###### 

ER-α relative binding affinities.

  Compound       IC~50~[a](#tfn8-ehp-116-1315){ref-type="table-fn"}   Relative affinity[b](#tfn9-ehp-116-1315){ref-type="table-fn"}(%)
  -------------- ---------------------------------------------------- ------------------------------------------------------------------
  E~2~           6.9 × 10^−10^                                        100
  DE-71          No effect                                            ---
  2,4-DBP        No effect                                            ---
  2,4,5-TBP      No effect                                            ---
  4′-OH-BDE-17   2.1 × 10^−6^                                         0.03
  2′-OH-BDE-28   6.0 × 10^−5^                                         0.001
  4-OH-BDE-42    1.4 × 10^−5^                                         0.005
  3-OH-BDE-47    5.2 × 10^−5^                                         0.001
  6-OH-BDE-47    1.1 × 10^−5^                                         0.001
  4′-OH-BDE-49   2.3 × 10^−6^                                         0.03

The concentration of test compound yielding 50% displacement of ^3^H-E~2~ from receptor, calculated based on data shown in [Figure 3](#f3-ehp-116-1315){ref-type="fig"}.

Relative affinity was calculated as E~2~ IC~50~ ÷ test chemical IC~50~ × 100.
